We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%

No holdings matched the selected filter criteria.

2 3 4 5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.